Stockscreener 앱 받기
16.97
2.13%
-0.37
시간 외 거래:
16.97
Eton Pharmaceuticals Inc 주식(ETON)의 최신 뉴스
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33% - simplywall.st
Eton Pharmaceuticals Inc expected to post earnings of 2 cents a shareEarnings Preview - TradingView
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025 - The Manila Times
Eton Pharmaceuticals to Report Q1 2025 Financial Results on May 13, 2025 - Nasdaq
Rare Disease Leader Eton Pharmaceuticals Sets Q1 2025 Earnings Date: Key Updates Coming May 13 - Stock Titan
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance
Q1 EPS Estimate for Eton Pharmaceuticals Boosted by Analyst - Defense World
JPMorgan Chase & Co. Acquires 51,238 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
B. Riley Raises Earnings Estimates for Eton Pharmaceuticals - Defense World
Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment - MSN
Eton Pharmaceuticals (ETON) Submits NDA for New Treatment for Ce - GuruFocus
Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment (ETON:NASDAQ) - Seeking Alpha
Eton Pharmaceuticals Submits NDA to FDA for ET-600 to Treat Central Diabetes Insipidus - marketscreener.com
Eton Pharmaceuticals Says FDA Review Expected To Take 10 Months, Potential Q1 2026 Launch - marketscreener.com
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) - GlobeNewswire
Groundbreaking Pediatric Diabetes Drug Advances: First-Ever Liquid Formulation Heads to FDA Review - Stock Titan
Geode Capital Management LLC Sells 4,050 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Large Increase in Short Interest - Defense World
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Has Found A Path To Profitability - Yahoo Finance
Needham Upgrades Neurocrine Biosciences to Buy From Hold, $138 Price Target - marketscreener.com
Raymond James Financial Inc. Makes New Investment in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Retail investors who have a significant stake must be disappointed along with institutions after Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) market cap dropped by US$35m - simplywall.st
(ETON) Technical Data - news.stocktradersdaily.com
Eton sells ex-U.S. rights for hormone disorder therapy to Esteve Pharma - MSN
Eton sells overseas rights for hormone disorder drug (ETON) - Seeking Alpha
Eton Pharmaceuticals Agrees to License International Rights for Increlex to Esteve Pharmaceuticals - MarketScreener
Eton Pharma Out-Licenses International Rights To Increlex To Esteve Pharma - Nasdaq
Eton Pharmaceuticals out-licenses international rights to Increlex - TipRanks
Eton Pharmaceuticals IncEsteve To Pay Eur4 Million Up Front For Increlex RightsSEC Filing - MarketScreener
Eton Pharmaceuticals licenses Increlex rights abroad - Investing.com
Eton Pharmaceuticals licenses Increlex rights abroad By Investing.com - Investing.com UK
Eton Pharmaceuticals Out-Licenses International Rights to Increlex® - GlobeNewswire
Major Pharma Deal: Eton's Smart Move Unlocks Global Market for Rare Disease Treatment - Stock Titan
Eton Pharmaceuticals Inc (ETON) Shares Down 4.87% on Mar 25 - GuruFocus
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - The Manila Times
REG-CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - TradingView
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency… - Informazione.it
Eton Pharmaceuticals Inc (ETON) Stock Price Down 3.79% on Mar 22 - GuruFocus
Q3 EPS Estimates for Eton Pharmaceuticals Lifted by B. Riley - Defense World
Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at HC Wainwright - Defense World
Research Analysts Set Expectations for ETON Q2 Earnings - Defense World
B. Riley Reiterates Buy Rating for Eton Pharmaceuticals (NASDAQ:ETON) - Defense World
Q1 EPS Forecast for Eton Pharmaceuticals Boosted by Analyst - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says - Defense World
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know - Benzinga
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript - Insider Monkey
B. Riley Raises Price Target on Eton Pharmaceuticals to $24 From $21, Keeps Buy Rating - MarketScreener
Eton Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo
Eton Pharmaceuticals Reports Record Q4 Revenue Growth - TipRanks
Eton Pharmaceuticals Reports Strong Growth and Strategic Acquisitions - TipRanks
Eton Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - TradingView
Eton Pharmaceuticals Reports Record Q4 2024 Revenue and Successful Product Launches Ahead of Investor Day Conference Call - Nasdaq
Eton Pharmaceuticals Achieves 16th Straight Quarter of Growth, Doubles Product Portfolio - StockTitan
Earnings Scheduled For March 18, 2025 - Benzinga
Eton Pharmaceuticals (NASDAQ:ETON) shareholder returns have been incredible, earning 421% in 5 years - Simply Wall St
1.20%
0.06%
자본화:
|
볼륨(24시간):